Published in Pharma Law Weekly, February 14th, 2006
The marketing approval was granted in the 25 member states of the European Union, Iceland, Liechtenstein and Norway. Under the approval, Cubicin is indicated for the treatment of complicated skin and soft-tissue infections (cSSTI) caused by Gram-positive bacteria. Cubicin is expected to become available in the United Kingdom and the Netherlands within the next few weeks, followed by additional European countries, in accordance with local legal regulations.
Gram-positive bacteria are a major cause of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.